Intra-Cellular Therapies, Inc. reiterated earnings guidance for the full year 2024. Full year 2024, the company reiterated CAPLYTA net product sales guidance of $645 to $675 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
69.48 USD | +0.60% | +1.76% | -3.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.55% | 7.29B | |
-0.12% | 92.26B | |
-2.63% | 38.11B | |
-12.32% | 32.9B | |
+66.54% | 26.51B | |
-12.95% | 15.75B | |
-6.29% | 13.36B | |
-10.50% | 11.65B | |
-49.11% | 10.12B | |
+187.82% | 9.78B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024